NSTEMI


Also found in: Acronyms.

NSTEMI

Non-ST elevation myocardial infarction

NSTEMI

non–ST-segment elevation myocardial infarction.
References in periodicals archive ?
The assessment and plan were reviewed for a differential diagnosis, five specific evidence-based therapies for NSTEMI, and treatments of other comorbidities.
6] Nonstandard abbreviations: NSTE-ACS, non-ST-elevation acute coronary syndrome; GRACE, Global Registry of Acute Coronary Events; NSTEMI, non-ST-elevation myocardial infarction; cTnT, cardiac troponin T; hs-cTnT, high-sensitivity cTnT; CRP, C-reactive protein; FGF23, fibroblast growth factor 23; GDF-15, growth differentiation factor 15; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sST2, soluble suppression of tumorigenicity 2; IQR, interquartile range; AUC, area under the ROC curve; IDI, integrated discrimination improvement; NRI, net reclassification improvement; OR, odds ratio.
Use of the combination of clopidogrel and ASA for up to 9 months is recommended for the medical management of NSTEMI.
The second research titledGlobal Acute Coronary Syndrome (ACS) Market 2015-2019 segments this industry into STEMI, NSTEMI, and UA with the forecast that worldwide acute coronary syndrome market will grow at 13.
Data definitions for the elements, including the definitions for the clinical endpoints of in-hospital mortality, NSTEMI, STEMI, heart failure, and cardiogenic shock, are available online (http://www.
Following NSTEMI, between 60 to 85% of cases demonstrate a patent infarct-related artery, (6,7) yet patients develop symptoms of myocardial ischemia and signs of myocardial necrosis, which reflect the importance not only of epicardial coronary artery occlusion/stenosis in the pathophysiology of acute myocardial ischemia, but also the importance of distal embolization of platelet-rich microaggregates of thrombus, with attendant 'micro-infarction' and independent effects on outcomes, regardless of flow in the epicardial artery.
In July 2012, a combined panel of experts from the ACCF and AHA updated their guidelines to include a Class I recommendation for the use of BRILINTA in patients with Unstable Angina (UA) or NSTEMI, managed both invasively or non-invasively.
5][6][7] The number of UA or NSTEMI ACS patients worldwide who are managed without acute coronary interventions, such as PCI, has ranged from 32 percent to almost 60 percent over the last few years.
The Global ACS market can be divided into three segments: STEMI, NSTEMI, and UA.
Seventy-nine patients, younger than 45 years old, with the diagnosis of NSTE-ACS (41 NSTEMI, 38 USAP) were included in the study.
3] Nonstandard abbreviations: MI, myocardial infarction; hs-cTnT, high- sensitivity cardiac troponin T; NSTEMI, non-ST-elevation MI; RCVs, reference change values; II, index of individuality; ED, emergency department; ACS, acute coronary syndrome; ECG, electrocardiogram; UAP, unstable angina pectoris; CV,, within-individual biological imprecision; [CV.
The clinical evidence for the effectiveness and safety of Effient is derived from the TRITON-TIMI 38 study, a 13,608-patient, multicenter, international, randomized, double-blind, parallel-group study comparing Effient to a regimen of clopidogrel, each added to aspirin (ASA) and other standard therapy, in patients with ACS (UA, NSTEMI, or STEMI) who were to be managed with PCI.